BostonGene

The AI engine Fit Assessment

Beta

BostonGene Corporation develops advanced biomedical software that utilizes AI for personalized therapy decision-making in cancer treatment, focusing on individual patient profiles and tumor characteristics. Their solutions include comprehensive molecular and immune profiling to optimize treatment options for patients.

Blurb

BostonGene is a biomedical software company for advanced patient analysis and personalized therapy in the fight against cancer.

HQ Location

Waltham (United States)

Founded

2015

Employees

201 - 500

Total funding raised

$200.00M

Funding Status

Series B, $150.00M, April 6, 2022
Subspaces
  • Drug Repurposing

BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and artificial intelligence. Built and validated through an extensive real-world clinical testing network, BostonGene’s Foundation Model of cancer and the immune system integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights. These insights enable biopharma partners to design and de-risk trials, identify novel targets, and optimize therapeutic response prediction across all stages of development while simultaneously improving patient care through clinically integrated innovation.